TABLE 7.

Clinical trials with rucaparib in ovarian cancer.

Name of the study	Year of the study	Phase of the study	Research group	Dose of rucaparib	Results
ARIEL3 (Clamp et al., 2021)	2021	III	564, (rucaparib group n = 375, placebo group n = 189)	Rucaparib 600 mg twice daily	Rucaparib group, placebo group: progression-free interval 6–≤12 months - PFS 8.2, 4.1 months; progression-free interval >12 months - PFS 13.6, 5.6 months, respectively
ATHENA-MONO/GOG-3020/ENGOT-ov45 (Monk et al., 2022)	2022	III	538, (rucaparib group n = 427, placebo group n = 111)	Rucaparib 600 mg twice daily	Rucaparib group, placebo group: HRD population - PFS 28.7, 11.3 months; HRD-negative population - PFS 9.2, 9.1 months, respectively
ARIEL4 (Kristeleit et al., 2022)	2022	III	349, (rucaparib only group n = 233, chemotherapy group n = 116)	Rucaparib 600 mg twice daily	Rucaparib only group, chemotherapy group: PFS 7.4, 5.7 months, respectively

PFS, progression-free survival; HRD, homologous recombination deficiency.